Literature DB >> 22310711

The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity.

Torsten B Meissner1, Amy Li, Yuen-Joyce Liu, Etienne Gagnon, Koichi S Kobayashi.   

Abstract

Major histocompatibility complex (MHC) class I and class II are crucial for the function of the human adaptive immune system. A member of the NLR (nucleotide-binding domain, leucine-rich repeat) protein family, NLRC5, has recently been identified as a transcriptional regulator of MHC class I and related genes. While a 'master regulator' of MHC class II genes, CIITA, has long been known, NLRC5 specifically associates with and transactivates the proximal promoters of MHC class I genes. In this study, we analyzed the molecular requirements of NLRC5 nuclear import and transactivation activity. We show that NLRC5-mediated MHC class I gene induction requires an intact nuclear localization signal and nuclear distribution of NLRC5. In addition, we find that the nucleotide-binding domain (NBD) of NLRC5 is critical not only for nuclear translocation but also for the transactivation of MHC class I genes. Changing the cellular localization of NLRC5 is likely to immediately impact MHC class I expression as well as MHC class I-mediated antigen presentation. NLRC5 may thus provide a promising target for the modulation of MHC class I antigen presentation, especially in the setting of transplant medicine.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22310711      PMCID: PMC3289513          DOI: 10.1016/j.bbrc.2012.01.104

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.

Authors:  K Masternak; A Muhlethaler-Mottet; J Villard; M Zufferey; V Steimle; W Reith
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

Review 2.  The bare lymphocyte syndrome and the regulation of MHC expression.

Authors:  W Reith; B Mach
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

Review 3.  Genetic control of MHC class II expression.

Authors:  Jenny Pan-Yun Ting; John Trowsdale
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

4.  CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.

Authors:  S B Hake; K Masternak; C Kammerbauer; C Janzen; W Reith; V Steimle
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

Review 5.  Transcriptional regulation of the MHC class II antigen presentation pathway.

Authors:  Jeremy M Boss; Peter E Jensen
Journal:  Curr Opin Immunol       Date:  2003-02       Impact factor: 7.486

6.  The NLR gene family: a standard nomenclature.

Authors:  Jenny P-Y Ting; Ruth C Lovering; Emad S Alnemri; John Bertin; Jeremy M Boss; Beckley K Davis; Richard A Flavell; Stephen E Girardin; Adam Godzik; Jonathan A Harton; Hal M Hoffman; Jean-Pierre Hugot; Naohiro Inohara; Alex Mackenzie; Lois J Maltais; Gabriel Nunez; Yasunori Ogura; Luc A Otten; Dana Philpott; John C Reed; Walter Reith; Stefan Schreiber; Viktor Steimle; Peter A Ward
Journal:  Immunity       Date:  2008-03       Impact factor: 31.745

Review 7.  NLRC5: a newly discovered MHC class I transactivator (CITA).

Authors:  Torsten B Meissner; Amy Li; Koichi S Kobayashi
Journal:  Microbes Infect       Date:  2011-12-22       Impact factor: 2.700

8.  Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes.

Authors:  C Spilianakis; J Papamatheakis; A Kretsovali
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

9.  CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter.

Authors:  G W Beresford; J M Boss
Journal:  Nat Immunol       Date:  2001-07       Impact factor: 25.606

10.  NLR family member NLRC5 is a transcriptional regulator of MHC class I genes.

Authors:  Torsten B Meissner; Amy Li; Amlan Biswas; Kyoung-Hee Lee; Yuen-Joyce Liu; Erkan Bayir; Dimitrios Iliopoulos; Peter J van den Elsen; Koichi S Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-16       Impact factor: 11.205

View more
  30 in total

1.  NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.

Authors:  Yikun Yao; Yalong Wang; Fuxiang Chen; Yin Huang; Shu Zhu; Qibin Leng; Hongyan Wang; Yufang Shi; Youcun Qian
Journal:  Cell Res       Date:  2012-04-10       Impact factor: 25.617

Review 2.  NLRC5/CITA: A Key Player in Cancer Immune Surveillance.

Authors:  Sayuri Yoshihama; Saptha Vijayan; Tabasum Sidiq; Koichi S Kobayashi
Journal:  Trends Cancer       Date:  2017-01-10

3.  NLRC5/MHC class I transactivator is a target for immune evasion in cancer.

Authors:  Sayuri Yoshihama; Jason Roszik; Isaac Downs; Torsten B Meissner; Saptha Vijayan; Bjoern Chapuy; Tabasum Sidiq; Margaret A Shipp; Gregory A Lizee; Koichi S Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

Review 4.  Expression regulation and function of NLRC5.

Authors:  Yikun Yao; Youcun Qian
Journal:  Protein Cell       Date:  2013-03-13       Impact factor: 14.870

Review 5.  NLRC5: new cancer buster?

Authors:  Feng Tang; Yadi Xu; Bing Zhao
Journal:  Mol Biol Rep       Date:  2020-01-10       Impact factor: 2.316

6.  NLRP2 is a suppressor of NF-ƙB signaling and HLA-C expression in human trophoblasts†,‡.

Authors:  Tamara Tilburgs; Torsten B Meissner; Leonardo M R Ferreira; Arend Mulder; Kiran Musunuru; Junqiang Ye; Jack L Strominger
Journal:  Biol Reprod       Date:  2017-04-01       Impact factor: 4.285

7.  ATP binding by NLRP7 is required for inflammasome activation in response to bacterial lipopeptides.

Authors:  Alexander D Radian; Sonal Khare; Lan H Chu; Andrea Dorfleutner; Christian Stehlik
Journal:  Mol Immunol       Date:  2015-07-02       Impact factor: 4.407

8.  NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients.

Authors:  Xiaoyu Li; Fuchun Guo; Yongmei Liu; Hui-Jiao Chen; Feng Wen; Binwen Zou; Dan Li; Qin Qin; Xiaoke Liu; Yali Shen; Yongsheng Wang
Journal:  Oncol Lett       Date:  2015-07-08       Impact factor: 2.967

9.  Cutting edge: impaired MHC class I expression in mice deficient for Nlrc5/class I transactivator.

Authors:  Amlan Biswas; Torsten B Meissner; Taro Kawai; Koichi S Kobayashi
Journal:  J Immunol       Date:  2012-06-18       Impact factor: 5.422

Review 10.  Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.

Authors:  Saptha Vijayan; Tabasum Sidiq; Suhail Yousuf; Peter J van den Elsen; Koichi S Kobayashi
Journal:  Immunogenetics       Date:  2019-01-31       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.